$1.19 Earnings Per Share Expected for Ionis Pharmaceuticals Inc (NASDAQ:IONS) This Quarter

Brokerages expect Ionis Pharmaceuticals Inc (NASDAQ:IONS) to post earnings per share of $1.19 for the current quarter, according to Zacks. Six analysts have provided estimates for Ionis Pharmaceuticals’ earnings. The highest EPS estimate is $1.39 and the lowest is $0.84. Ionis Pharmaceuticals reported earnings per share of $2.42 during the same quarter last year, which suggests a negative year over year growth rate of 50.8%. The firm is expected to announce its next quarterly earnings results on Wednesday, February 26th.

According to Zacks, analysts expect that Ionis Pharmaceuticals will report full year earnings of $1.99 per share for the current fiscal year, with EPS estimates ranging from $1.64 to $2.17. For the next year, analysts expect that the firm will report earnings of $0.19 per share, with EPS estimates ranging from ($1.43) to $1.08. Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover Ionis Pharmaceuticals.

Ionis Pharmaceuticals (NASDAQ:IONS) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.18 earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.49. Ionis Pharmaceuticals had a return on equity of 36.31% and a net margin of 52.26%. The company had revenue of $168.00 million during the quarter, compared to analysts’ expectations of $152.47 million. During the same period last year, the business earned ($0.03) earnings per share. Ionis Pharmaceuticals’s quarterly revenue was up 15.9% on a year-over-year basis.

A number of equities research analysts have recently commented on the company. Bank of America assumed coverage on Ionis Pharmaceuticals in a research report on Wednesday, November 13th. They set a “buy” rating and a $70.00 target price on the stock. Wells Fargo & Co upped their price target on Ionis Pharmaceuticals from $90.00 to $120.00 and gave the stock an “outperform” rating in a report on Thursday, October 10th. Zacks Investment Research upgraded Ionis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $65.00 price target on the stock in a research report on Saturday, November 16th. Cowen reissued a “hold” rating on shares of Ionis Pharmaceuticals in a report on Thursday, November 7th. Finally, William Blair initiated coverage on Ionis Pharmaceuticals in a report on Thursday, November 14th. They issued a “market perform” rating on the stock. Seven research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $75.55.

In other news, CFO Elizabeth L. Hougen sold 4,000 shares of the firm’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $58.80, for a total transaction of $235,200.00. Following the completion of the transaction, the chief financial officer now directly owns 24,055 shares in the company, valued at $1,414,434. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Joseph Klein III sold 2,000 shares of Ionis Pharmaceuticals stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $60.00, for a total value of $120,000.00. Following the completion of the sale, the director now directly owns 13,495 shares of the company’s stock, valued at $809,700. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 37,154 shares of company stock worth $2,333,382. Company insiders own 2.40% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of IONS. Ladenburg Thalmann Financial Services Inc. boosted its position in shares of Ionis Pharmaceuticals by 1.0% during the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 16,084 shares of the company’s stock worth $1,040,000 after acquiring an additional 154 shares in the last quarter. Comerica Bank lifted its stake in Ionis Pharmaceuticals by 1.1% during the second quarter. Comerica Bank now owns 15,590 shares of the company’s stock worth $1,051,000 after purchasing an additional 170 shares during the last quarter. Coastal Investment Advisors Inc. boosted its holdings in Ionis Pharmaceuticals by 1.7% in the second quarter. Coastal Investment Advisors Inc. now owns 10,023 shares of the company’s stock valued at $640,000 after purchasing an additional 172 shares in the last quarter. Rehmann Capital Advisory Group increased its stake in Ionis Pharmaceuticals by 41.3% in the second quarter. Rehmann Capital Advisory Group now owns 592 shares of the company’s stock valued at $38,000 after purchasing an additional 173 shares during the last quarter. Finally, Kistler Tiffany Companies LLC increased its stake in Ionis Pharmaceuticals by 9.9% in the third quarter. Kistler Tiffany Companies LLC now owns 2,006 shares of the company’s stock valued at $120,000 after purchasing an additional 181 shares during the last quarter. 85.65% of the stock is currently owned by institutional investors and hedge funds.

IONS stock traded down $0.79 during midday trading on Monday, hitting $63.82. 26,383 shares of the stock traded hands, compared to its average volume of 834,670. The firm has a market cap of $9.10 billion, a P/E ratio of 21.56, a PEG ratio of 2.32 and a beta of 1.91. The company has a debt-to-equity ratio of 0.44, a current ratio of 10.39 and a quick ratio of 10.31. The stock’s fifty day simple moving average is $58.46 and its 200-day simple moving average is $62.98. Ionis Pharmaceuticals has a 1-year low of $48.27 and a 1-year high of $86.58.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Recommended Story: The limitations of an equal weight rating

Get a free copy of the Zacks research report on Ionis Pharmaceuticals (IONS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.